Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114224 | 0.86 | GRM5 (0.50) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL12201476 | 0.86 | GRM5 (0.56) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL12201477 | 0.85 | GRM5 (0.52) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL4103735 | 0.85 | GRM5 (0.52) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL2520163 | 0.83 | GRM5 (0.49) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL4109054 | 0.83 | GRM5 (0.49) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL2668369 | 0.83 | GRM5 (0.48) | GRM5FFAR2PDF | |
| SCHEMBL4114293 | 0.81 | GRM5 (0.46) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL4103721 | 0.79 | GRM5 (0.47) | GRM5HCAR3RAB9ANPC1CXCR2 | |
| SCHEMBL2513021 | 0.77 | GRM5 (0.46) | GRM5FFAR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173645-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008116107-A2 | PIPERAZINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GRM5 2182/4885HCAR3 3290/4885RAB9A 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.